Trial | NCT01481402  Report issue

Title

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)
Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    liothyronine ...

  • Study Participants

    21
Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.
The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.
Study Started
Jul 31
2011
Primary Completion
Feb 28
2014
Study Completion
Feb 28
2014
Last Update
Jul 16
2019

Drug Liothyronine

Liothyronine 40 microgram per day

  • Other names: T3

Drug Liothyronine

3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)

  • Other names: T3

Placebo-liothyronine Placebo Comparator

3 months of placebo followed by 3 months of Liothyronine treatment.

Liothyronine-Placebo Other

3 months of Liothyronine treatment followed by 3 months of Placebo treatment.

Criteria 

Inclusion Criteria:

Patients with stable, chronic systolic heart failure
T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal
LVEF ≤ 45 % on prior echocardiography

Exclusion Criteria:

Established thyroid illness
Atrial fibrillation/flutter
More than 20% ventricular extrasystoles
Severe chronic obstructive lung disorder
Pregnancy. Pregnancy testing will be done for fertile women
Age < 18 years
No Results Posted